← All trials
NCT05883449
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 10, 2023
- Primary completion
- Apr 30, 2026
- Completion date
- Nov 30, 2027
- First posted
- Jun 1, 2023
- Last posted
- Dec 29, 2023
- Enrollment
- 154
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Affimed GmbHLead sponsor
- Affimed GmbHStudy director
- Artiva Biotherapeutics, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.